Table 4b.
Persistent symptoms in fibrotic and non fibrotic patients.
| No Fibrosis | Post Covid Fibrosis | P value (no. of observations) | OR (95% CI) unadjusted | OR (95% CI) adjusted | |
|---|---|---|---|---|---|
| Breathlessness | 106 (31.6%) | 29 (82.9%) | <0.001* (370) | 10.44 (4.21–25.91) | 5.25 (1.86–14.81)b |
| Cough | 64 (19.1%) | 19 (54.3%) | <0.001*(370) | 5.03 (2.45–10.32) | |
| Chest pain | 28 (8.5%) | 11 (31.4%) | <0.001*(366) | 4.96 (2.2–11.17) | |
| Fatigue | 136 (40.7%) | 29 (82.9%) | <0.001*(366) | 7.04 (2.84–17.41) | |
| Myalgia | 54 (16.3%) | 21 (61.8%) | <0.001*(366) | 8.32 (3.93–17.62) | 1.68 (0.65–4.36)b |
| MRC pre-Covida | 1 (1–2) | 1 (1–1) | 0.008* (320) | ||
| MRC post-Covida | 2 (2–4) | 3 (2–4) | 0.099 (141) | ||
| Δ MRCa | 1 (0–1) | 2 (1–3) | 0.001* (140) | ||
| CAT scorea | 6 (2–10) | 14 (7–18) | 0.001* (348) | ||
| CAT ≥10 | 89 (28.4%) | 24 (68.6%) | 0.001* (348) | 5.49 (2.58–11.68) |
Data presented as Frequency (%) compared using Chi square test except.
a
Median (interquartile range) compared using Mann-Whitney U test *significant.
b
Adjusted for male sex, persistent breathlessness, myalgia, invasive ventilation, Peak WBC and high risk CXR during COVID-19 admission.